Catabasis Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Catabasis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Catabasis Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.
Catabasis Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypertriglyceridemia, with 2 trials.
Top-decile sponsor footprint
Catabasis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
12 total, page 1 of 1
Study of Edasalonexent With Midazolam and Deflazacort in Healthy Subjects
NCT04543370
An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT03917719
Phase III Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
NCT03703882
Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy
NCT02439216
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
NCT02608697
A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects
NCT02374047
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
NCT01968720
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
NCT01912560
A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003
NCT01725594
A Study of CAT-1004 Biomarkers in Healthy Subjects
NCT01670773
A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes
NCT01511900
Safety, Tolerability, and Pharmacokinetic Study of CAT-1004 in Healthy Adult Volunteers
NCT01440166
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 3 |
| Phase 3 | 2 |
How the Catabasis Pharmaceuticals early-phase archive is shaped
12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).
Phase mix: 2 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Hypertriglyceridemia (2 trials), 8 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Catabasis Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Catabasis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 archived trials
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Catabasis Pharmaceuticals page
12 registered trials is a research-attention snapshot, not an endorsement of Catabasis Pharmaceuticals or any single study.
- None of Catabasis Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Hypertriglyceridemia is the condition Catabasis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypertriglyceridemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Catabasis Pharmaceuticals pipeline card: 12 registered trials from official public datasets.Report a data error.